Informe nº Osteba D12-04. - Euskadi.net

haloperidol. Psychopharmacology. 1995;118: 52-56.75. Lee SH, Yang YY. Reversible neurotoxicity inducedby a combination of clozapine and lithium:a case report.Chung Hua i Hsueh TsaChih - Chin Med J. 1999; 62(3): 184-7.76. Lieberman JA, Kane JM, Jhons CA. Clozapine:Guidelines for clinical management. J ClinPsychiatry. 1989; 50: 329-338.77. Lieberman JA, Yunis J, Egea E et al. HLA-B38,DR4, DQW 3 and clozapina-induced agranulocitosisin jewish patients with schizophrenia.Arch Gen Psychiatry. 1990; 47: 945-948.78. Lieberman JA, Saffeman AZ, Pollack S,Szymanski S, Johns C, Howard A, Kronig M,Bookstein P, Kane JM. Clinical effects of clozapinein chronic schizophrenia: response totreatment and predictors of outcome. Am JPsychiatry. 1994; 151: 1.744-1.752.79. Lieberman JA. Maximizing clozapine therapy:managing side effects. J Clin Psychiatry.1998; 59 (suppl 3): 38-43.80. Lindenmayer JP, Gochowski S, Mabugat L.Clozapine effects on positive and negativesymptoms: a six month trial in treatment-refractoryschizophrenic. J Clin Psychopharmacol.1994; 14: 201-204.81. Llorca PM, Lancon C, Disdier B , Farisse J,Sapin C, Auquier P. Effectiveness of clozapinein neuroleptic-resistant schizophrenia: clinicalresponse and plasma concentrations.JPsychiatry Neurosci. 2002; 27 (1): 30-7.82. Llorca PM, Pere JJ. Leponex 10 ans après-Unerevue Clinique L’Encephale. 2004; XXX: 474-91.85. McEvoy y cols. Treatment of schizophrenia1999. The expert consensus guideline series.J Clin Psychiatry. 1999; 60 Suppl 11: 3-80.86. McEvoy JP, Lieberman JA, Stroup TS, DavisSM, Meltzer HY, Rosenheck RA, Swartz MS,Perkins DO, Keefe RSE, Davis CE, Severe J,Hsiao JK, for the CATIE Investigators. Effectivenessof clozapine versus olanzapine, quetiapine,and risperidone in patients withchronic schizophrenia who did not respondto prior atypical antipsychotic treatment. AmJ Psychiatry. 2006; 163: 600-610.87. Meltzer HY, Bastani B, Kwon KY, Ramirez LF,Burnett S, Sharpe J. A prospective study ofclozapine in treatment-resistant schizophrenicpatients.I Preliminary Report. Psychopharmacology(Berlin). 1989; 99 Suppl:S68-72.88. Metzer HY. The effect of clozapine and otheratypical antipsychotic drugs on negativesymptoms. In Marneros A, Andreasen NC,Tsuang MT eds, negative versus Positiveschizophrenia (Springer-Verlag: Heidelberg1991). 1991; 365-75.89. Meltzer HY. Treatment of the neurolepticnonresponsiveschizophrenic patient. SchizophrBull. 1992;18: 515-542.90. Meltzer HY, McGurk SR. The effects of clozapina,risperidona and olanzapine on cognitivefunction in schizophrenia. SchizophrBull. 1999; 25: 233-255.91. Meltzer HY & Okayli G. Reduction of suicidalityduring clozapina treatment of neuroleptic-resistantschizophrenics: impact on riskbenefit assessment. Am J Psychiatry. 1995;152: 183-190.esTRaTegIas83. Longo LP, Salzman C. Valproic acid effectson serum concentrations of clozapine andnorclozapine. Am J Psychiatry. 1995; 152(4):650.84. Marder SR, Essock SM, Miller AL, BuchananRW, Davis JM, Kane JM, Lieberman J, SchoolerNR. The Mount Sinai Conference on thePharmacotherapy of schizophrenia. SchizophrBull. 2002; 28(1): 5-16.92. Meltzer HY, Alphs L, Green AI, Altamura C,Anand R, Bertoldi A, Bourgeois M, Chouinard G,Islam MZ, Kane J, Krishnan R, Lindenmayer JP,Potkin S, for the InerSePT Study Group. Clozapinetreatment for suicidality in schizophrenia.International suicide prevention trial (Inter-SePT) Arch Gen Psychiatry. 2003; 60: 82-91.93. Meyer JM [Ed], Nasrallah HA [Ed]. Medical ilnessand schizophrenia (2nd ed.). xvi, 455 pp.113